VILDOFF-M 50/500MG TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus (to improve blood glucose control along with diet and exercise), especially when blood sugar is not adequately controlled with metformin or other oral antidiabetic medicines

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), leading to increased insulin release and reduced glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production and improves insulin sensitivity, lowering blood glucose levels.

Oral tablet. Take as prescribed by a doctor, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew. Regularly monitor blood glucose and follow diet/exercise advice.

Nausea, vomiting, diarrhea, abdominal pain, loss of appetite, metallic taste, headache, dizziness, upper respiratory tract infection, hypoglycaemia (more likely with other antidiabetics), increased liver enzymes

Prescription-only antidiabetic. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, heavy alcohol use, severe infection, heart/respiratory failure; stop and seek care if rapid breathing, severe weakness, abdominal pain occur. Use caution in renal impairment; dose adjustment/avoid based on eGFR. Vildagliptin may affect liver—check LFTs periodically and stop if persistent elevation or jaundice. Risk of pancreatitis—seek care for severe persistent abdominal pain. Temporarily withhold metformin before/after iodinated contrast or major surgery as advised. Not for type 1 diabetes or diabetic ketoacidosis.